Drug intelligence / Profile preview

LHRH-a + Cimicifuga racemosa

Development stage: Preclinical
Lead developer: Schaper & Bruemmer
Modality: Small Molecules
Administration: Intramuscular, Subcutaneous, Oral

Overview

This combination involves **Luteinizing Hormone-Releasing Hormone analogue (LHRH-a)**, which is used to treat conditions like breast cancer by suppressing hormone production, and **Cimicifuga racemosa (Black Cohosh)**, a herbal supplement traditionally used to alleviate menopausal symptoms. The combination is studied for its effectiveness in managing menopausal syndrome caused by LHRH-a therapy in breast cancer patients. Cimicifuga racemosa does not significantly affect hormone levels but may help reduce menopausal symptoms without estrogenic activity[1][2][3].

Targets

MOR (Mu opioid receptor)5-HT (Serotonin receptors)GnRHR (Gonadotropin-releasing hormone receptor)

Beyond the preview

Go deeper on LHRH-a + Cimicifuga racemosa.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LHRH-a + Cimicifuga racemosa.

Explore the full profile